ISSN: 1859 - 2872
Myelin oligodendrocyte glycoprotein antibody-associated disease: Two case reports at Viet Tiep Friendship Hospital, Hai Phong
Main Article Content
Keywords
Abstract
Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is a relatively newly recognized autoimmune disorder characterized by antibodies targeting myelin oligodendrocyte glycoprotein (MOG), predominantly affecting the brain, optic nerves, and spinal cord, and often leading to altered consciousness and behavior, visual impairment, and focal neurological deficits. Clinically, MOG antibody–associated encephalomyelitis presents with heterogeneous manifestations and is frequently misdiagnosed as other demyelinating disorders of the central nervous system, including multiple sclerosis (MS), aquaporin-4 antibody–positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), or acute disseminated encephalomyelitis (ADEM). We report two cases of MOGAD diagnosed and treated with corticosteroid therapy at the Department of Neurology, Viet Tiep Friendship Hospital.
Article Details
References
2. Mariotto S, Ferrari S, Monaco S, Benedetti MD, Farinazzo A, Alberti D et al (2017) Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. J Neurol 264(12): 2420-2430. doi:10.1007/s00415-017-8635-4.
3. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22(3): 268-282.
4. Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2): 89-102. doi:10.1038/s41582-018-0112-x.
5. Sechi E, Gastaldi M, Cortese R, Bisceglia A et al (2026) International recommendations for the management of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). J Neuroimmunol 410: 578781.